If we just focused on those patients with hematological malignancies (all PTLD in our cohort), there were 4 with localized disease and 7 with advanced disease in the mTOR inhibitor group while there were 1 with localized disease and 6 with advanced disease in the non-conversion group. This evidence concerns the gene MTOR and post-transplant lymphoproliferative disease.